1. Introduction {#sec1-ijms-18-01404}
===============

Post-translational modifications of histone proteins in eukaryotic cells serve as crucial regulatory mechanisms of gene expression and are important for maintaining genomic integrity \[[@B1-ijms-18-01404],[@B2-ijms-18-01404]\]. The histone modifications, such as its acetylation, methylation, phosphorylation, and ubiquitination, influence genomic activity by altering the binding force of DNA to histones or by acting as marks that recruit specific histone binding proteins \[[@B2-ijms-18-01404]\]. Among these histone modifications, methylation has been implicated in heterochromatin formation and the regulation of promoter activity \[[@B3-ijms-18-01404],[@B4-ijms-18-01404]\]. The histone residues, on which methylation occurs, include the following lysine and arginine residues: H3 (K4, 9, 27, 36, and 79), H4K20, H3 (R2, 8, 17, and 26), and H4R3 \[[@B5-ijms-18-01404],[@B6-ijms-18-01404]\] ([Figure 1](#ijms-18-01404-f001){ref-type="fig"}a). These methylation sites are evolutionarily well conserved \[[@B7-ijms-18-01404]\]. A variety of histone methyltransferases (writers), histone demethylases (erasers), and methylated histone binding proteins (readers) have been identified in various eukaryotic genomes \[[@B8-ijms-18-01404]\]. Their site-specific molecular functions have been defined by biochemical and genetic studies \[[@B2-ijms-18-01404],[@B8-ijms-18-01404]\] ([Table 1](#ijms-18-01404-t001){ref-type="table"}).

Dysregulation of epigenetic modifications are associated with various human diseases, including neurodevelopmental disorders \[[@B9-ijms-18-01404],[@B10-ijms-18-01404]\]. In particular, an increasing number of mutations in histone lysine methylation-related genes have been identified as intellectual disability-associated genes by exome sequencing with patients' samples \[[@B11-ijms-18-01404],[@B12-ijms-18-01404],[@B13-ijms-18-01404],[@B14-ijms-18-01404]\] ([Figure 1](#ijms-18-01404-f001){ref-type="fig"}b and [Table 2](#ijms-18-01404-t002){ref-type="table"}). This highlights the importance of proper control of histone methylation during neurogenesis. In the current article, we provide an overview of the latest updates on the pathological implication of alterations in histone lysine methylation status in terms of neurodevelopmental disorders. Through this, we try to predict the future direction of research on this emerging field.

2. Histone Lysine Methylations and Related Factors {#sec2-ijms-18-01404}
==================================================

In most cases, methylation of histone H3 lysine 4 (H3K4me) is primarily found at enhancers and promoters of actively transcribed genes, and the methylation status of genes (i.e., mono-, di-, tri-methylation) correlates with its transcriptional activity \[[@B15-ijms-18-01404],[@B16-ijms-18-01404]\]. Members of the lysine methyl transferase 2 (KMT2) family catalyze the addition of methyl groups to H3K4 at the post-translational level, while lysine demethylases (KDMs) remove the methyl groups. This dynamically modulates chromatin structures \[[@B17-ijms-18-01404],[@B18-ijms-18-01404]\]. The KMT2 family, which is highly conserved throughout eukaryotes, can be evolutionarily divided into three subgroups (i.e., KMT2A and KMT2B, KMT2C and KMT2D, and SETD1A and SETD1B) \[[@B4-ijms-18-01404],[@B19-ijms-18-01404]\]. In addition, SMYD2 and SETD3 also have been identified as H3K4 methyltransferases, and eight KDMs are reported to target the H3K4me \[[@B4-ijms-18-01404],[@B20-ijms-18-01404]\].

Methylation of histone H3 lysine 9 (H3K9me) is associated with both heterochromatin formation and gene silencing in euchromatin \[[@B2-ijms-18-01404]\]. H3K9me acts as a binding sit *Counseling*, e for HP1 \[[@B21-ijms-18-01404],[@B22-ijms-18-01404]\] which forms a complex with chromatin-modifying factors crucial for heterochromatin formation when recruited to H3K9me \[[@B23-ijms-18-01404],[@B24-ijms-18-01404]\]. In the euchromatic region, H3K9me contributes to HP1-mediated gene silencing \[[@B25-ijms-18-01404]\]. H3K9me is catalyzed by several methyltransferases, such as EHMT1, EHMT2, SUV39H1, SUV39H2, SETDB1, dimeric EHMT1-EHMT2, and the PRDM family, and erased by the following lysine demethylases: KDM1, KDM3, KDM4, PHF2, and PHF8 \[[@B8-ijms-18-01404],[@B26-ijms-18-01404],[@B27-ijms-18-01404]\].

Histone H3 lysine 27 methylation (H3K27me) is a repressive chromatin mark that is involved in gene silencing during development and X-chromosome inactivation \[[@B28-ijms-18-01404],[@B29-ijms-18-01404]\]. H3K27me is associated with the repression of developmental regulator genes in human and murine embryonic stem cells (ESCs) \[[@B30-ijms-18-01404],[@B31-ijms-18-01404]\]. Intriguingly, a variety of promoters characteristically contain both H3K4me3 (an activating mark) and H3K27me (a repressive mark) in pluripotent ESCs, which is referred to as "bivalency." The change in the bivalent situation is associated with differentiation \[[@B32-ijms-18-01404]\]. H3K27me, catalyzed by EZH1 or EZH2 containing Polycomb Repressive Complex (PRC) 2, is a binding site for PRC1 to compact chromosomes \[[@B33-ijms-18-01404]\]. KDM6A, KDM6B, and UTY have been identified as erasers of H3K27me \[[@B8-ijms-18-01404]\].

A role of methylation on histone H3 lysine 36 (H3K36me) has initially been reported in the activation of genes in various systems \[[@B34-ijms-18-01404]\]. However, H3K36me also functions in various processes, including alternative splicing \[[@B35-ijms-18-01404]\], dosage compensation \[[@B36-ijms-18-01404]\], DNA damage response \[[@B37-ijms-18-01404]\], and transcriptional repression \[[@B38-ijms-18-01404]\], depending on the chromatin context. H3K36me is tightly regulated by multiple KMTs and KDMs \[[@B20-ijms-18-01404]\]. In vitro and in vivo studies, to date, have demonstrated that there are the following eight types of KMTs regulating H3K36 methylation levels in humans: SETD2, SETD3, NSD1, NSD2, NSD3, ASH1L, SMYD2, and SETMAR \[[@B20-ijms-18-01404]\]. Although all H3K36-specific methyltransferases contain highly conserved SET domains, the patterns of H3K36 methylation vary. Most H3K36 KMTs preferentially mono- and di-methylate the residue, whereas SETD2 is the only enzyme that catalyzes H3K36me3 and requires mono- or di-methylated H3K36 for its function \[[@B39-ijms-18-01404]\]. Conversely, methylated H3K36 can be demethylated by six KDMs. The H3K36 KDMs, which all belong to the Jumonji protein family, contain the conserved JmjC domain consisting of the following three groups: JHDM1 (KDM2A, KDM2B), JHDM3 (KDM4A, KDM4B, KDM4C), and RIOX1 \[[@B40-ijms-18-01404]\]. JHDM1 is specific for H3K36me1/me2 demethylation, whereas JHDM3 uses H3K36 and H3K9 residues as substrates for the me2/me3-specific demethylation \[[@B41-ijms-18-01404]\]. Similarly, in addition to H3K36me2/me3-specific activity, RIOX1 preferentially demethylates H3K4me1/me3 residues \[[@B42-ijms-18-01404]\].

Histone H3 lysine 79 methylation (H3K79me) is associated with a diverse range of cellular processes including telomeric silencing, cellular development, cell-cycle checkpoint, DNA repair, and transcription regulation \[[@B43-ijms-18-01404]\]. However, only one H3K79-specific KMT is known, with no KDM for H3K79 demethylation reported to date. DOT1L is the sole enzyme that is responsible for all three forms of H3K79 methylation in humans \[[@B44-ijms-18-01404]\]. In addition, DOT1L is unique because it is the only non-SET domain containing methyltransferase, which has been identified to date \[[@B18-ijms-18-01404]\].

Methylation on Histone H4 lysine 20 (H4K20me) displays various biological processes depending on its methylated levels. H4K20me1 is associated with transcriptional activation, appearing in the most highly transcribed group of genes with other core modifications at active promoters \[[@B45-ijms-18-01404]\]. H4K20me2 has distinct roles, such as marking points of replication origin and damage response in the DNA \[[@B46-ijms-18-01404],[@B47-ijms-18-01404]\]. Conversely, H4K20me3 is associated with transcriptional repression at promoters and silencing of repetitive DNA and transposons \[[@B45-ijms-18-01404],[@B48-ijms-18-01404]\]. H4K20me is catalyzed by three enzymes, with activities restricted to specific methylation states. KMT5A, the first identified H4K20 methyltransferase, is the only H4K20me1 enzyme \[[@B49-ijms-18-01404]\]. H4K20me1 can be further di- and tri-methylated by KMT5B and KMT5C \[[@B50-ijms-18-01404]\]. Similarly, several distinct demethylases are involved in the removal of specific H4K20me. PHF8 acts as a demethylase for H4K20me1 \[[@B51-ijms-18-01404]\]. Intriguingly, as previously described, PHF8 is the KDM that has additional activities towards H3K9me1 and H3K9me2 \[[@B8-ijms-18-01404]\]. In addition, LSD1n, an alternatively spliced form of KDM1A, demethylates H4K20me1 and H4K20me2 \[[@B52-ijms-18-01404]\], while PHF2 displays demethylase activity on H4K20me3 \[[@B53-ijms-18-01404]\].

3. Neurodevelopmental Disorders Related with Histone Lysine Methylations {#sec3-ijms-18-01404}
========================================================================

3.1. H3K4 Methylation {#sec3dot1-ijms-18-01404}
---------------------

### 3.1.1. KMT2A and Wiedemann-Steiner Syndrome {#sec3dot1dot1-ijms-18-01404}

Mutations in *KMT2A* were reported to be associated with Wiedemann-Steiner syndrome (WDSTS; OMIM 605130), an extremely rare neurodevelopmental condition accompanied by microcephaly, short stature, autism-like phenotype, and aggression \[[@B54-ijms-18-01404]\]. Interestingly, these abnormal brain functions were recapitulated in *KMT2A* heterozygous mutant mice, which displayed profound deficits in long-term contextual fear memory \[[@B55-ijms-18-01404],[@B56-ijms-18-01404]\]. In particular, neuronal ablation of *KMT2A* in the postnatal forebrain and adult prefrontal cortex exhibited increased anxiety and robust cognitive deficits in mice. In the same study, the analyzing H3K4me3 level and the gene expression profiles in *KMT2A*-deficient cortical neurons revealed that the homeodomain transcription factor, MEIS2, was repressed in these mice. Moreover, *MEIS2* knockdown in prefrontal cortex phenocopied memory defects elicited by the deletion of *KMT2A* \[[@B57-ijms-18-01404]\], thus proposing a critical role of MEIS2 in the pathogenesis of WDSTS.

### 3.1.2. KMT2D and Kabuki Syndrome 1 {#sec3dot1dot2-ijms-18-01404}

The most well-studied neurodevelopmental disorder associated with dysregulated H3K4me is Kabuki syndrome 1 (KABUK1; OMIM 147920), which is a rare congenital syndrome characterized by a distinctive face (a reminiscent of the make-up of actors Kabuki, traditional Japanese music-drama) and mental retardation with additional features including autism, seizure, and microcephaly \[[@B58-ijms-18-01404]\]. Heterozygous mutations in *KMT2D* were found in more than 50% of patients with KABUK1, with the majority of mutations resulting in the premature termination of the protein product. In addition, mutations in *KDM6A*, an H3K27me demethylase gene, were also reported to contribute to less than 10% of this syndrome, and this type is referred as Kabuki syndrome 2 (KABUK2; OMIM 300867) \[[@B59-ijms-18-01404],[@B60-ijms-18-01404],[@B61-ijms-18-01404],[@B62-ijms-18-01404]\]. Recently, Bögershausen et al. identified two mutations in *RAP1A/B*, which encode the Ras family small GTPases, in patients with KABUK1 by whole exome sequencing \[[@B61-ijms-18-01404]\]. The authors also demonstrated that mutant *RAP1* morphant phenocopied *KDM6A* and *KMT2D* mutants in zebrafish, and that the MEK/ERK pathway signaling was perturbed in *RAP1*- and *KMT2D*-defective cells. Interestingly, these phenotypes were rescued by treatment with an MEK inhibitor. On the other hands, the reduction in neurogenesis and hippocampal memory defects exhibited in a KABUK1 mouse model were ameliorated by the treatment with a histone deacetylase (HDAC) inhibitor, AR-42 \[[@B63-ijms-18-01404]\]. Furthermore, a ketogenic diet rescued hippocampal memory defects through the elevation of beta-hydroxybutyrate, an endogenous HDAC inhibitor, in the same mice model \[[@B64-ijms-18-01404]\]. Taken together, these results potentially provide diverse therapeutic directions to treat, or at least mitigate, the symptoms of KABUK1.

### 3.1.3. SETD1A and Schizophrenia {#sec3dot1dot3-ijms-18-01404}

Extensive exome sequencing from over 200 patients with schizophrenia (SCZD; OMIM 181500) revealed two de novo mutations in *SETD1A*, which likely cause malfunction of SETD1A activity \[[@B65-ijms-18-01404]\]. Furthermore, a strong association between the loss-of-function mutation of *SETD1A* and SCZD was confirmed by analyzing the whole exome sequencing of over 4000 patients with SCZD \[[@B66-ijms-18-01404]\]. Interestingly, a recent bioinformatic analysis demonstrated that in addition to mutations in the protein coding region, mutations in the regulatory elements of *SETD1A* also contributed to the etiology of SCZD. De novo synonymous mutations within frontal cortex-derived DNase I-hypersensitive sites were enriched in SCZD, and *SETD1A* was identified as the highest statistical significant gene \[[@B67-ijms-18-01404]\].

### 3.1.4. H3K4me Demethylases and Neurodevelopmental Disorders {#sec3dot1dot4-ijms-18-01404}

Given the intimate association between H3K4 methylation and neurodevelopment disorders, it is rational to assume that KDMs that are responsible for demethylation of H3K4me can be also mutated in neurodevelopmental disorders. Indeed, homozygous missense mutation in *KDM5A* has been reported in an individual with intellectual disability \[[@B68-ijms-18-01404]\]. Furthermore, *KDM5C*, another H3K4 demethylase coding gene, has been recurrently mutated in patients with mental retardation, X-linked, syndromic, Claes-Jensen type (MRXSCJ; OMIM 300534) \[[@B68-ijms-18-01404],[@B69-ijms-18-01404],[@B70-ijms-18-01404]\]. Intriguingly, *KDM5C* has been shown to be transcriptionally regulated by ARX, a homeobox transcription factor, which is frequently mutated in X-linked mental retardation and epilepsy \[[@B71-ijms-18-01404],[@B72-ijms-18-01404],[@B73-ijms-18-01404],[@B74-ijms-18-01404]\]. Additionally, a missense mutation in amine oxidase domain of KDM1A has been reported in patients with mixed features of KABUK1 and KBG syndrome (KBGS; OMIM 148050), which are characterized by macrodontia, distinctive craniofacial findings, and intellectual disability \[[@B75-ijms-18-01404]\]. It is noteworthy that KDM1A catalyzes the demethylation of mono- and di-methylated H3K4, while other KDMs can demethylate H3K4me1/2/3 \[[@B76-ijms-18-01404]\].

### 3.1.5. PHF21A and Potocki-Shaffer Syndrome {#sec3dot1dot5-ijms-18-01404}

Besides H3K4me writers and erasers, PHF21A, an unmethylated H3K4 reader, was associated with a neurodevelopmental disorder. *PHF21A* was translocated in patients with Potocki-Shaffer syndrome (PSS; OMIM 601224), characterized by multiple exostoses, parietal foramina, intellectual disability, and craniofacial anomalies \[[@B77-ijms-18-01404],[@B78-ijms-18-01404],[@B79-ijms-18-01404]\]. This translocation commonly results in deletion of the PHD domain coding region of *PHF21A*, suggesting that dictation of unmethylated H3K4 is crucial for its functions. Accordingly, the deficiency of head development was observed in *PHF21A* morpholino-injected zebrafish, and this defect was rescued by injection of human *PHF21A* mRNA \[[@B78-ijms-18-01404]\]. In addition, PHF21A, in combination with KDM1A, is a key component of the BHC complex, which is involved in the repression of neuron-specific genes \[[@B80-ijms-18-01404]\]. Furthermore, *SCN3A*, a KDM1A target gene, was derepressed, and LSD1 occupancy at the *SCN3A* promoter was reduced in *PHF21A*-translocated lymphoblastoid cell lines \[[@B78-ijms-18-01404]\], hence proposing the idea that interplay between KDM1A and PHF21A is indispensable for normal brain development.

3.2. H3K9 Methylation {#sec3dot2-ijms-18-01404}
---------------------

### 3.2.1. EHMT1 and Kleefstra Syndrome {#sec3dot2dot1-ijms-18-01404}

Mutations in *EHMT1*, a gene encoding H3K9 methyltransferase, have been associated with Kleefstra syndrome (KS; OMIM 610253) which is characterized by intellectual disability, childhood hypotonia, and distinctive facial features \[[@B81-ijms-18-01404],[@B82-ijms-18-01404]\]. Previously, this syndrome was known as the 9q Subtelomeric Deletion syndrome, in which minimal critical deleted region comprises *EHMT1* \[[@B83-ijms-18-01404]\]. In agreement with the role of EHMT1 on neurodevelopment in human, both *Drosophila EHMT* mutants and *EHMT1* heterozygous knockout mice showed deficits in dendrite branching, learning, and memory \[[@B84-ijms-18-01404],[@B85-ijms-18-01404]\]. Recent studies revealed the functions of EHMT1 in neurons, which may explain the phenotypes of patients and animal models of KS. A study measuring network and single cell activity in cortical cultures showed that EHMT1 is important for cortical neuronal network development \[[@B86-ijms-18-01404]\]. Additionally, EHMT1 mediates homeostatic synaptic scaling, which stabilizes the activity of neural networks by balancing excitation and inhibition \[[@B87-ijms-18-01404]\]. Interestingly, recent studies using exome sequencing revealed that the KS phenotypic spectrum was also linked to mutations in *KMT2B* and *KMT2C* \[[@B88-ijms-18-01404],[@B89-ijms-18-01404]\], and these suggest that complicated epigenetic modules might underlie the pathogenesis of KS.

### 3.2.2. PHF8 and Siderius X-Linked Mental Retardation Syndrome {#sec3dot2dot2-ijms-18-01404}

Siderius X-linked mental retardation syndrome (MRXSSD; OMIM 300263) is an X-linked intellectual disability condition; patients display mental retardation, a long face and broad nasal tip, and cleft lip and palate \[[@B90-ijms-18-01404],[@B91-ijms-18-01404]\]. MRXSSD has been associated with mutations in *PHF8* \[[@B91-ijms-18-01404],[@B92-ijms-18-01404],[@B93-ijms-18-01404]\]. Interestingly, PHF8 has a histone lysine demethylase activity towards three different methylated lysines on histones, H3K9me1/2 and H4K20me1 \[[@B94-ijms-18-01404],[@B95-ijms-18-01404],[@B96-ijms-18-01404]\], and also functions as a trimethylated H3K4 reader \[[@B94-ijms-18-01404]\].

Loss of a *PHF8* homolog in *Caenorhabditis elegans* resulted in axon guidance defects via the alteration of Hedgehog-like signaling \[[@B97-ijms-18-01404]\]. Furthermore, injection of zebrafish *PHF8* morpholino caused brain and craniofacial development defects \[[@B96-ijms-18-01404]\], thus suggested a critical role of histone methylation dynamics regulated by PHF8 in MRXSSD. However, surprisingly, a recent study showed that *Phf8*-deficient mice had no obvious developmental defects and cognitive impairment, while *Phf8*-deficient primary cells had reduced the proliferative potential \[[@B98-ijms-18-01404]\]. The results in mice indicated that MRXSSD is not simply caused by a single *PFH8* mutation, but rather by its combination with other genetic or environmental factors at the same time. The different phenotypes exhibited by some animal models and varying degrees of intellectual disability of human patients with MRXSSD can be attributed to the various targets and complex functions of PHF8.

3.3. H3K27 Methylation {#sec3dot3-ijms-18-01404}
----------------------

### EZH2 and Weaver Syndrome

Weaver syndrome (WVS; OMIM 277590) is an autosomal dominant disorder characterized by overgrowth and intellectual disability \[[@B99-ijms-18-01404],[@B100-ijms-18-01404],[@B101-ijms-18-01404]\]. Exome sequencing studies identified *EZH2* as a causative gene of WVS \[[@B102-ijms-18-01404],[@B103-ijms-18-01404]\]. EZH2 interacts with EED to form PRC2, which is an H3K27me3 methyltransferase complex \[[@B104-ijms-18-01404]\]. Interestingly, mutations in *EED* were found in individuals displaying symptoms similar to those of WVS \[[@B14-ijms-18-01404],[@B105-ijms-18-01404]\], suggesting that the dysregulation of H3K27 methylation is responsible for these symptoms.

Several studies have shown that *EZH2* deficiencies in animal models induced abnormal neurogenesis in the cerebral cortex \[[@B106-ijms-18-01404]\], cerebellum \[[@B107-ijms-18-01404]\], and spinal cord \[[@B108-ijms-18-01404]\] during embryonic development. Moreover, *EZH2* is also implicated in adult hippocampal neurogenesis \[[@B109-ijms-18-01404]\]. The alteration of neurogenesis induced by *EZH2* deficiencies has been associated with various neurogenic processes, such as the reduction of neural progenitor cell proliferation \[[@B108-ijms-18-01404],[@B109-ijms-18-01404],[@B110-ijms-18-01404]\], cell fate change \[[@B106-ijms-18-01404],[@B107-ijms-18-01404],[@B111-ijms-18-01404],[@B112-ijms-18-01404],[@B113-ijms-18-01404]\], and neuronal migration \[[@B114-ijms-18-01404],[@B115-ijms-18-01404],[@B116-ijms-18-01404]\]. These results suggest that EZH2-induced H3K27 methylation plays an important role in various processes of neurodevelopment, dysfunction of which might be closely related to intellectual disability in patients with WVS.

3.4. H3K36 Methylation {#sec3dot4-ijms-18-01404}
----------------------

### 3.4.1. NSD1 Defects in Sotos Syndrome 1 and Beckwith-Wiedemann Syndrome {#sec3dot4dot1-ijms-18-01404}

Recent studies demonstrated that disrupted levels or patterns of H3K36 methylation can cause a range of human diseases, including neurodevelopmental disorders. Among them, Sotos syndrome 1 (SOTOS1; OMIM 117550) represents an important human model system for studying the neurodevelopmental outcome of epigenetic dysregulation, which is caused by mutations in *NSD1* \[[@B117-ijms-18-01404]\]. SOTOS1 is an autosomal dominant disorder characterized by pre- and postnatal overgrowth, facial dysmorphism, macrocephaly, and non-progressive neurological delay \[[@B118-ijms-18-01404]\]. Interestingly, amplified genomic events of *NSD1* resulted in the opposite phenotypic outcome of SOTOS1, so that duplication in *NSD1* led to reversed clinical phenotypes of SOTOS1 with microcephaly, as well as delayed bone age, indicating the importance of proper *NSD1* expression during brain development \[[@B119-ijms-18-01404]\]. In addition, it was shown that neuroblastoma and glioma may occur in human in the absence of *NSD1* function \[[@B120-ijms-18-01404]\]. Although the MAPK/ERK pathway was mapped as a downstream signaling pathway of *NSD1*-related overgrowth of stature in SOTOS1 \[[@B121-ijms-18-01404]\], until recently, the molecular mechanisms how dysregulated NSD1 affects the mental retardation in SOTOS1 patients remains elusive. To date, two Sotos-like overgrowth syndromes called as Sotos syndrome 2 (SOTOS2; OMIM 614753) and 3 (SOTOS3; OMIM 617169) have been reported, which are caused by mutations in the *NFIX* and *APC2* genes, respectively \[[@B122-ijms-18-01404],[@B123-ijms-18-01404]\]. Among the products of the two genes, APC2, a WNT signaling pathway regulator, has recently been suggested as a crucial target of NSD1, of which defects may cause the intellectual disability associated with SOTOS \[[@B123-ijms-18-01404]\]. In the mouse model system, *Apc2* deficiency caused impaired learning and memory abilities along with an abnormal head shape. In addition, *Nsd1* knockdown downregulated endogenous *Apc2* expression, and defective neuronal phenotypes caused by the knockdown were rescued by the forced expression of *Apc2*, suggesting that *APC2* may be a critical downstream gene of NSD1 in human neuronal cells.

Beckwith-Wiedemann syndrome (BWS; OMIM 130650) is another distinct overgrowth disorder with a broad clinical spectrum including hypoglycemia, ear creases/pits, cleft palate, and predisposition to embryonal tumors \[[@B124-ijms-18-01404]\]. Martinez-y-Martinez et al. documented that mental retardation was observed in 6 of the 39 BWS cases \[[@B125-ijms-18-01404]\]. It is well known that a major cause of BWS is the dysregulation of imprinted growth regulatory genes on chromosome 11p15 \[[@B126-ijms-18-01404]\]. Interestingly, mutations in the *NSD1* gene have been identified in 2 patients among 52 individuals clinically diagnosed with BWS, which suggests the involvement of *NSD1* in imprinting of the 11p15 region \[[@B127-ijms-18-01404]\].

### 3.4.2. NSD2 and Wolf-Hirshhorn Syndrome {#sec3dot4dot2-ijms-18-01404}

*NSD2* is one of the major genes associated with Wolf-Hirshhorn syndrome (WHS; OMIM 194190), of which key features include severe growth and mental retardation, microcephaly, "Greek helmet" facies, and closure defects \[[@B128-ijms-18-01404]\]. Like patients with WHS, mice with *Nsd2* gene deletions were growth-retarded, showed midline, craniofacial, and ocular anomalies \[[@B129-ijms-18-01404]\]. However, these mice did not show any learning deficits \[[@B129-ijms-18-01404]\]. Although the downstream effectors of NSD2, such as RUNX2 and p300, which are known to play a role in bone development \[[@B130-ijms-18-01404]\], have been identified, the mechanism by which *NSD2* deficiency causes neurological disorders in patients with WHS is still unknown.

3.5. H4K20 Methylation {#sec3dot5-ijms-18-01404}
----------------------

### Siderius X-Linked Syndromic Mental Retardation and Meier-Gorlin Syndrome 1

Thus far, two developmental diseases associated with dysregulated H4K20 methylation have been reported in human. As described above, one is MRXSSD (OMIM 300263) caused by mutations in *PHF8*, which encodes an eraser of H3K9 and H4K20 methylation. The other is Meier-Gorlin syndrome 1 (MGORS1; OMIM 224690) caused by homozygous or compound heterozygous mutation in the *ORC1* gene \[[@B131-ijms-18-01404]\], which encodes a specific reader of H4K20me2 \[[@B46-ijms-18-01404]\]. MGORS1 is a rare disorder characterized by severe intrauterine, postnatal growth retardation, and microcephaly \[[@B132-ijms-18-01404]\]. Interestingly, however, despite the presence of microcephaly, intellects of patients with MGORS1 are usually normal \[[@B133-ijms-18-01404]\].

4. Perspectives {#sec4-ijms-18-01404}
===============

As reviewed above, the pathogenesis of various neurodevelopmental disorders is closely associated with alterations in histone methylation status, which, in many cases, can be primarily attributed to loss-of-function mutations in related factors. Given that histone methylation status is meticulously regulated by the balance between two opposing enzymes (i.e., KMTs and KDMs), pharmaceutical inhibition of specific targets counteracting the loss-of-function mutations responsible for diseases can be a possible therapeutic option. Interestingly, a subset of currently available psychotherapeutic drugs, such as the atypical antipsychotic Clozapine, the mood-stabilizer Valproate, and the antidepressant Phenelzine are known to interfere with histone methylation in the brain \[[@B134-ijms-18-01404]\], although the relative contribution of this interference to their psychotherapeutic effects remains to be elucidated. In principle, an estimated 100 lysine and arginine residue-specific histone methyltransferases and demethylases \[[@B135-ijms-18-01404]\] can be reasonable therapeutic targets, since they are considered more specific than HDACs \[[@B134-ijms-18-01404]\]. Of note, histone methylation has been the most flourishing area of epigenetics research recently, and in line with this, huge efforts have been made to develop several potential therapeutic molecules, which specifically regulate histone methyltransferases and methylation reader proteins, particularly for cancer treatment \[[@B136-ijms-18-01404]\]. For example, selective inhibitors, such as EPZ005687, GSK126, and EI1, which target EZH2 of PRC2, were recently reported by three independent groups to inhibit proliferation of B-cell lymphomas harboring EZH2-activating mutations \[[@B137-ijms-18-01404],[@B138-ijms-18-01404],[@B139-ijms-18-01404]\]. In addition, tranylcypromine derivatives and polyaminoguanidine derivatives were designed and characterized to inhibit histone demethylases with potential anti-cancer activity \[[@B136-ijms-18-01404]\]. Several epigenetic compounds, such as ORY-1001 and GSK2879552, are currently undergoing clinical trials for cancer treatment. If they meet the required biosafety standards, they could potentially be strong candidates for treating neurodevelopmental disorders, by correcting the impaired histone methylation status. Moreover, a microRNA-based gene silencing strategy targeting a specific histone methyltransferase or demethylase can be an alternative therapeutic option to consider in this regard. Indeed, several studies have reported the important roles of miRNA in histone methylation and following transcriptional gene silencing in various model systems \[[@B140-ijms-18-01404],[@B141-ijms-18-01404],[@B142-ijms-18-01404]\]. Although further research is warranted, it will be interesting to establish whether these epigenetic compounds and/or microRNA-based specific gene silencing approaches have obvious therapeutic benefits for the patients with the neurodevelopmental disorders outlined in this review.
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Aristaless related homeobox

ASH1L

ASH1 like histone lysine methyltransferase

BHC complex

BRAF35/histone deacetylase complex

BWS

Beckwith-Wiedemann syndrome

DOT1L

DOT1 like histone lysine methyltransferase

EED

Embryonic ectoderm development

EHMT1

Euchromatic histone lysine methyltransferase 1

EHMT2

Euchromatic histone lysine methyltransferase 2

ERK

Extracellular signal-regulated kinase

ESC

Embryonic stem cells

EZH1

Enhancer of zeste 1 polycomb repressive complex 2 subunit

EZH2

Enhancer of zeste 2 polycomb repressive complex 2 subunit

FAD

Flavin adenosine dinucleotide

H3K4

Histone H3 lysine 4

H3K4me

Methylation on histone H3 lysine 4

H3K9

Histone H3 lysine 9

H3K9me

Methylation on histone H3 lysine 9

H3K27

Histone H3 lysine 27

H3K27me

Methylation on histone H3 lysine 27

H3K36

Histone H3 lysine 36

H3K36me

Methylation on histone H3 lysine 36

H3K79

Histone H3 lysine 79

H3K79me

Methylation on histone H3 lysine 79

H3R2

Histone H3 arginine 2

H3R8

Histone H3 arginine 8

H3R17

Histone H3 arginine 17

H3R26

Histone H3 arginine 26

H4K20

Histone H4 lysine 20

H4K20me

Methylation on histone H4 lysine 20

H4R3

Histone H4 arginine 3

HDAC

Histone deacetylase

HP1

Heterochromatin protein 1

JHDM

JmjC-domain containing histone demethylases

JmjC

Jumonji C

KABUK1

Kabuki syndrome 1

KABUK2

Kabuki syndrome 2

KBGS

KBG syndrome

KS

Kleefstra syndrome

LSD1n

Lysine-specific demethylase 1 variant

KDM

Lysine demethylase

KMT

Lysine methyl transferase

MAPK

Mitogen-activated protein kinase

MEIS2

Myeloid ecotropic viral integration site 1 homolog 2

MEK

Mitogen-activated protein kinase kinase

MGORS1

Meier-Gorlin syndrome 1

MRXSCJ

Mental retardation, X-linked, syndromic, Claes-Jensen type

MRXSSD

Siderius X-linked mental retardation syndrome

NFIX

Nuclear factor I X

NSD1

Nuclear receptor-binding SET domain protein 1

NSD2

Nuclear receptor-binding SET domain protein 2

NSD3

Nuclear receptor-binding SET domain protein 3

ORC1

Origin recognition complex subunit 1

PHF2

PHD finger protein 2

PHF21A

PHD finger protein 21A

PHF8

PHD finger protein 8

PRC1

Polycomb repressive complex 1

PRC2

Polycomb repressive complex 2

PRDM

PR/SET domain family

PSS

Potocki-Shaffer syndrome

RAP1A/B

RAS-related protein 1A/B

RIOX1

Ribosomal oxygenase 1

RUNX2

Runt related transcription factor 2

SCZD

Schizophrenia

SCN3A

Sodium voltage-gated channel alpha subunit 3

SETD1A

SET domain containing 1A

SETD1B

SET domain containing 1B

SETD2

SET domain containing 2

SETD3

SET domain containing 3

SETDB1

SET domain bifurcated 1

SETMAR

SET domain and mariner transposase fusion gene

SMYD2

SET and MYND domain containing 2

SOTOS1

Sotos syndrome 1

SOTOS2

Sotos syndrome 2

SOTOS3

Sotos syndrome 3

SUV39H1

Suppressor of variegation 3-9 homolog 1

SUV39H2

Suppressor of variegation 3-9 homolog 2

UTY

Ubiquitously transcribed tetratricopeptide repeat containing, Y-linked

WDSTS

Wiedemann-Steiner syndrome

WHS

Wolf-Hirshhorn syndrome

WVS

Weaver syndrome

![Histone methylation and neurodevelopmental disorders: (**a**) histone methylation sites in the tails of histone H3 and H4; and (**b**) histone methyltransferases, demethylases, and methylated histone binding proteins linked with neurodevelopmental disorders. Five methylation sites were associated with several neurodevelopmental disorders. BWS, Beckwith-Wiedemann syndrome; KABUK1/2, Kabuki syndrome 1/2; KBGS, KBG syndrome; KS, Kleefstra syndrome; MGORS1, Meier-Gorlin syndrome 1; MRXSCJ, Mental retardation, X-linked, syndromic, Claes-Jensen type; MRXSSD, Siderius X-linked mental retardation syndrome; PSS, Potocki-Shaffer syndrome; SCZD, Schizophrenia; SOTOS1, Sotos syndrome 1; WDSTS, Wiedemann-Steiner syndrome; WHS, Wolf-Hirshhorn syndrome; WVS, Weaver syndrome.](ijms-18-01404-g001){#ijms-18-01404-f001}

ijms-18-01404-t001_Table 1

###### 

The names of the histone methylation-related factors mentioned in this paper and their synonyms.

  Symbol                                                                                                     Previous Symbol               Synonym(s)                                                              Residue             Function
  ---------------------------------------------------------------------------------------------------------- ----------------------------- ----------------------------------------------------------------------- ------------------- -------------------------
  ASH1L                                                                                                      ASH1L                         ASH1, ASH1L1, huASH1, KMT2H                                             H3K36               Methyltransferase
  DOT1L                                                                                                      DOT1L                         DOT1, KIAA1814, KMT4                                                    H3K79               Methyltransferase
  EHMT1                                                                                                      EHMT1                         bA188C12.1, Eu-HMTase1, FLJ12879, KIAA1876, KMT1D                       H3K9                Methyltransferase
  EHMT2                                                                                                      BAT8, C6orf30                 Em:AF134726.3, G9A, KMT1C, NG36/G9a                                     H3K9                Methyltransferase
  EZH1                                                                                                       EZH1                          KIAA0388, KMT6B                                                         H3K27               Methyltransferase
  EZH2                                                                                                       EZH2                          ENX-1, EZH1, KMT6, KMT6A                                                H3K27               Methyltransferase
  KDM1A                                                                                                      AOF2, KDM1                    BHC110, KIAA0601, LSD1                                                  H3K4, H3K9, H4K20   Demethylase
  KDM2A                                                                                                      FBXL11, KDM2A                 CXXC8, DKFZP434M1735, FBL11, FBL7, FLJ00115, JHDM1A, KIAA1004, LILINA   H3K36               Demethylase
  KDM2B                                                                                                      FBXL10, KDM2B                 CXXC2, Fbl10, JHDM1B, PCCX2                                             H3K36               Demethylase
  KDM3A                                                                                                      JMJD1, JMJD1A, KDM3A          JHMD2A, KIAA0742, TSGA                                                  H3K9                Demethylase
  KDM3B                                                                                                      C5orf7, JMJD1B, KDM3B         KIAA1082, NET22                                                         H3K9                Demethylase
  KDM4A                                                                                                      JMJD2, JMJD2A, KDM4A          JHDM3A, KIAA0677, TDRD14A                                               H3K9, H3K36         Demethylase
  KDM4B                                                                                                      JMJD2B, KDM4B                 KIAA0876, TDRD14B                                                       H3K9, H3K36         Demethylase
  KDM4C                                                                                                      JMJD2C, KDM4C                 GASC1, KIAA0780, TDRD14C                                                H3K9, H3K36         Demethylase
  KDM5A                                                                                                      JARID1A, KDM5A, RBBP2         \-                                                                      H3K4                Demethylase
  KDM5C                                                                                                      JARID1C, KDM5C, MRX13, SMCX   DXS1272E, XE169                                                         H3K4                Demethylase
  KDM6A                                                                                                      KDM6A, UTX                    \-                                                                      H3K27               Demethylase
  KDM6B                                                                                                      JMJD3, KDM6B                  KIAA0346                                                                H3K27               Demethylase
  KMT2A                                                                                                      KMT2A, MLL                    ALL-1, CXXC7, HRX, HTRX1, MLL1A, TRX1                                   H3K4                Methyltransferase
  KMT2B                                                                                                      KMT2B                         CXXC10, HRX2, KIAA0304, MLL1B, MLL2, MLL4, TRX2, WBP7                   H3K4                Methyltransferase
  KMT2C                                                                                                      KMT2C, MLL3                   HALR, KIAA1506                                                          H3K4                Methyltransferase
  KMT2D                                                                                                      KMT2D, MLL2, TNRC21           ALR, CAGL114, MLL4                                                      H3K4                Methyltransferase
  KMT5A                                                                                                      KMT5A, SETD8                  PR-Set7, SET07, SET8                                                    H4K20               Methyltransferase
  KMT5B                                                                                                      KMT5B, SUV420H1               CGI-85                                                                  H4K20               Methyltransferase
  KMT5C                                                                                                      KMT5C, SUV420H2               MGC2705                                                                 H4K20               Methyltransferase
  NSD1                                                                                                       STO                           ARA267, FLJ22263, KMT3B                                                 H3K36               Methyltransferase
  NSD2                                                                                                       WHSC1                         KMT3G, MMSET                                                            H3K36               Methyltransferase
  NSD3                                                                                                       WHSC1L1                       FLJ20353, KMT3F, WHISTLE                                                H3K36               Methyltransferase
  ORC1                                                                                                       ORC1L                         HSORC1, PARC1                                                           H4K20               Recognition
  PHF2                                                                                                       \-                            CENP-35, JHDM1E, KDM7C, KIAA0662                                        H3K9, H4K20         Demethylase
  PHF8                                                                                                       \-                            JHDM1F, KDM7B, KIAA1111, ZNF422                                         H3K9, H4K20/H3K4    Demethylase/Recognition
  PHF21A                                                                                                     \-                            BHC80, BM-006, KIAA1696                                                 H3K4                Recognition
  RIOX1                                                                                                      C14orf169                     FLJ21802, JMJD9, MAPJD, NO66                                            H3K4, H3K36         Demethylase
  SETD1A                                                                                                     \-                            KIAA0339, KMT2F, Set1                                                   H3K4                Methyltransferase
  SETD1B                                                                                                     \-                            KIAA1076, KMT2G, Set1B                                                  H3K4                Methyltransferase
  SETD2                                                                                                      \-                            FLJ23184, HIF-1, HYPB, KIAA1732, KMT3A                                  H3K36               Methyltransferase
  SETD3                                                                                                      C14orf154                     FLJ23027                                                                H3K4, H3K36         Methyltransferase
  SETDB1                                                                                                     SETDB1                        ESET, KG1T, KIAA0067, KMT1E, TDRD21                                     H3K9                Methyltransferase
  SETMAR                                                                                                     \-                            Mentase                                                                 H3K4, H3K36         Methyltransferase
  SMYD2                                                                                                      \-                            HSKM-B, KMT3C, ZMYND14                                                  H3K4, H3K36         Methyltransferase
  SUV39H1                                                                                                    SUV39H                        KMT1A                                                                   H3K9                Methyltransferase
  SUV39H2                                                                                                    SUV39H2                       KMT1B FLJ23414                                                          H3K9                Methyltransferase
  UTY                                                                                                        UTY                           KDM6AL, KDM6C                                                           H3K27               Demethylase
  The names of the proteins are followed by HUGO Gene Nomenclature Committee (<http://www.genenames.org/>)                                                                                                                             
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###### 

Neurodevelopmental disorders caused by mutations in histone methylation-related genes.

  Disorder                                                              OMIM     Symptom                                                                                                                                                                                                                                                                                                               Gene                   Residue           Function
  --------------------------------------------------------------------- -------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ----------------- -------------------------------------------------------
  Beckwith-Wiedemann syndrome (BWS)                                     130650   Pediatric overgrowth disorder involving a predisposition to tumor development                                                                                                                                                                                                                                         *NSD1*                 H3K36             Methyltransferase
  Kabuki syndrome 1                                                     147920   Congenital mental retardation, postnatal dwarfism, peculiar faces, broad and depressed nasal tip, large prominent earlobes, cleft or high-arched palate, scoliosis, short fifth finger, and persistence of finger pads                                                                                                *KMT2D KDM6A*          H3K4 H3K27        Methyltransferase Demethylase
  Kabuki syndrome 2 (KABUK1/2)                                          300867                                                                                                                                                                                                                                                                                                                                                                  
  KBG syndrome (KBGS)                                                   148050   Macrodontia of the upper central incisors, distinctive craniofacial findings, short stature, skeletal anomalies, neurologic involvement that includes global developmental delay, seizures, and intellectual disability                                                                                               *KDM1A*                H3K4 H3K9 H4K20   Demethylase Demethylase Demethylase
  Kleefstra syndrome (KS)                                               610253   Severe mental retardation, hypotonia, epileptic seizures, flat face with hypertelorism, synophrys, anteverted nares, everted lower lip, carp mouth with macroglossia, and heart defects                                                                                                                               *KMT2B, KMT2C EHMT1*   H3K4 H3K4 H3K9    Methyltransferase Methyltransferase Methyltransferase
  Meier-Gorlin syndrome 1 (MGORS1)                                      224690   Severe intrauterine and postnatal growth retardation, microcephaly, bilateral microtia, and aplasia or hypoplasia of the patellae                                                                                                                                                                                     *ORC1*                 H4K20             Recognition
  Mental retardation, X-linked, syndromic, Claes-Jensen type (MRXSCJ)   300534   Severe mental retardation, slowly progressive spastic paraplegia, facial hypotonia, and maxillary hypoplasia                                                                                                                                                                                                          *KDM5C*                H3K4              Demethylase
  Potocki-Shaffer syndrome (PSS)                                        601224   Craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina                                                                                                                                                                                                 *PHF21A*               H3K4              Recognition
  Schizophrenia (SCZD)                                                  181500   Hallucinations and delusions, severely inappropriate emotional responses, disordered thinking and concentration, erratic behavior, as well as social and occupational deterioration                                                                                                                                   *SETD1A*               H3K4              Methyltransferase
  Siderius X-linked mental retardation syndrome (MRXSSD)                300263   Mental retardation, a repaired cleft lip, a long face with broad nasal tip, long hands with long thin fingers, and flat feet with long thin toes                                                                                                                                                                      *PHF8*                 H3K4 H3K9 H4K20   Recognition Demethylase Demethylase
  Sotos syndrome 1 (SOTOS1)                                             117550   Excessively rapid growth, acromegalic features, and non-progressive cerebral disorder with mental retardation                                                                                                                                                                                                         *NSD1*                 H3K36             Methyltransferase
  Weaver syndrome (WVS)                                                 277590   Pre- and postnatal overgrowth, accelerated osseous maturation, characteristic craniofacial appearance, and developmental delay, broad forehead and face, ocular hypertelorism, prominent wide philtrum, micrognathia, deep horizontal chin groove, and deep-set nails                                                 *EZH2*                 H3K27             Methyltransferase
  Wiedemann-Steiner syndrome (WDSTS)                                    605130   Hypertrichosis cubiti associated with short stature, consistent facial features, including long eyelashes, thick or arched eyebrows with a lateral flare, down slanting and vertically narrow palpebral fissures, mild to moderate intellectual disability, behavioral difficulties, and hypertrichosis on the back   *KMT2A*                H3K4              Methyltransferase
  Wolf-Hirschhorn syndrome (WHS)                                        194190   Pre- and postnatal growth deficiency, developmental disability of variable degree, characteristic craniofacial features, and a seizure disorder                                                                                                                                                                       *NSD2*                 H3K36             Methyltransferase

[^1]: These authors contributed equally to this work.
